Avonisys AG: Avonisys AG wins patent litigation case against Synova SA
Swiss Federal Patent Court rules in favour of Avonisys AG in all relevant aspects and convicts Synova SA under the unfair competition act:
- Swiss Federal Patent Court confirms: no infringement of Synova’s CH/EP 1833636 H1 (partial renunciation of EP1833636B1 in Switzerland)
- Synova is convicted under the unfair competition act (UWG)
- Synova has to cover 80% of the costs of the court case
With its verdict released on March 31, 2021, the Swiss Federal Patent Court concluded that Avonisys’ patented Air-Jet technology does not infringeSynova’s CH/EP 1833636 H1. During the proceedings, Synova felt compelled to partially waive the original Swiss part of the patent in suit (EP 1833636 B1) and to substantially limit the scope of the patent claims to avoid patent invalidation following significant prior art brought up by Avonisys AG.
“We clearly appreciate the court’s decision which confirms our view that the Air-Jet feature stands in its own right and does not infringe. Our patented Air-Jet is one of the key innovations Avonisys has contributed to the waterjet laser technology, establishing a new and unmatched performance benchmark”, comments Jens Gaebelein, one of the founders and CTO of Avonisys.
Furthermore, the verdict holds that Synova violated the Unfair Competition Act (UWG) by approaching market participants with misleading information and unfounded threats relating to the infringement proceedings. The verdict demands Synova to release corrective information to every party contacted previously. Continuing such misleading activities in the future would result in fines against Synova.
“From the start in 2013, it has been Avonisys’ policy to build a solid IP base for its innovative hardware and process technology, which is underlined by more than 30 validated patents. We defend our technology vigorously against unfounded allegations. Customers around the globe value the reliability and ease-of-use of our products and appreciate to have a choice”, adds Jeroen Hribar, co-founder and CSO of Avonisys.
The verdict is subject to a 30 day recourse period for the parties and only then will be firm and final.
About Avonisys AG:
Avonisys develops, builds and sells laser systems based on its proprietary waterjet laser technology. Avonisys’ systems are designed to deliver robust performance for demanding applications while keeping operations simple and maintenance cost-effective.
- Picture is available at AP Images (http://www.apimages.com) -
Dr. Stephan Mohren
Chairman of the Board
6300 Zug, Switzerland
Tel: +41 (0) 41 229 48 73
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Grünenthal Group: Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee12.4.2021 11:47:13 CEST | Press release
With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee. MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief. (Aachen, Germany) –Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The investigational medicine is currently concluding Phase II of clinical development and is about to enter Phase III. Initial data showed a long-lasting and significant analgesic effect and function
Fluxergy, Inc. Receives CE-IVD Marking for a One-Hour COVID-19 RT-PCR Test and Positions for European Market Entry12.4.2021 09:00:00 CEST | Press release
IRVINE, CA., April 12, 2021 – Fluxergy, Inc., a medical diagnostic testing platform company with a detection technology solution capable of multimodality, announced today that it has obtained CE marking for its one-hour COVID-19 RT-PCR test, to use by healthcare professionals as an in vitro diagnostic (IVD) for the detection of SARS-CoV-2. The CE-mark will allow Fluxergy’s innovative testing platform to enter the European Union market and any other markets that accept CE-marking as valid regulatory approval. Fluxergy’s platform is an automated, sample-to-answer testing platform with multimodal capability allowing for a variety of assay types, such as molecular, immunochemistry, chemistry, and cytometry assays, to be run simultaneously on the same cartridge. This will give users the ability to run unique Point-of-Care (PoC) panels with the potential ability to do built-in reflex testing, among other capabilities. Potential environments for rapid testing applications include emergency ro
Grunenthal Group: Grünenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks7.4.2021 11:39:12 CEST | Press release
• Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among its peers in the pharmaceutical subindustry • Grünenthal is categorized as “medium risk”, placing it ahead of its key subindustry peers and in the same league as multinational companies like Pfizer and Roche (Aachen, Germany): Grünenthal, a global science-based pharmaceutical company, today announced that Sustainalytics, a Morningstar company and a globally-recognized provider of ESG research, ratings and data, has assessed it as having overall medium ESG risk. In addition, Sustainalytics acknowledged that Grünenthal has a strong management of its ESG risks. This places Grünenthal in the top five percent of the global pharmaceuticals subsector. “The long-term success of companies can no longer be measured by financial success alone. As a science-based company, Grünenthal strives to make a net-positive impact on the society,” said Gabriel Baertschi, CEO Grünenthal. “While we are proud to
Path2Integrity: MORE THAN 200 STUDENTS FROM ACROSS EUROPE TACKLE FAKE NEWS7.4.2021 09:54:12 CEST | Press release
A Europe-wide workshop on Fake News with Rainer Wieland, Vice-President of the European Parliament aims to identify reliable information and encourage responsible action.
DocMorris: Introducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life6.4.2021 09:15:56 CEST | Press release
The Novo Nordisk and Zur Rose Group collaboration presents DocMorris Adipositas Care, a digital hub which provides people living with obesity a new way to find the right care. Adipositas Care thoughtfully empowers people living with obesity by enabling them to learn about obesity and discover possible care solutions, to link to specialized advisors, doctors and digital solutions in obesity care, and by supporting them with the testimonials of peers who took action to better manage their health, all within one digital location. The program launches today in Germany with the intention to expand across other European markets.
MTIP AG: MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation 1.4.2021 09:00:00 CEST | Press release
MTIP AG, a Basel-based private equity firm that invests in healthtech companies, is pleased to announce that it has completed the first closing of its Fund II. The growth capital fund secured EUR 130m and is well on track towards the target fund size of EUR 200m.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom